Loading...
Loading...
Browse all stories on DeepNewz
VisitFirst organization to license HACE by mid-2025?
Dana-Farber Cancer Institute • 25%
A major pharmaceutical company • 25%
A biotech startup • 25%
Other • 25%
Official licensing announcements and press releases
New CRISPR Tool HACE Enables Long-Range Targeted Mutagenesis in Mammalian Genomes Published in Science Magazine
Oct 11, 2024, 02:30 PM
A new CRISPR-based tool called Helicase-Assisted Continuous Editing (HACE) has been developed for long-range, targeted mutagenesis of over 1000 base pairs in mammalian genomes. This tool allows researchers to explore the effects of genetic variants on gene function and regulation in both coding and non-coding regions. The research, co-authored by Brad E. Bernstein from Dana-Farber Cancer Institute and published in Science Magazine, expands the functional genomics toolbox. It demonstrates that HACE can continuously generate mutations over a 10-day period and enables targeting using dCas9 without introducing DNA nicks.
View original story
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Yes • 50%
No • 50%
United Nations • 25%
European Union • 25%
Arab League • 25%
Other • 25%
Merck • 25%
Hansoh Pharma • 25%
Joint Venture • 25%
Other • 25%
National Disability Rights Network • 25%
American Association of People with Disabilities • 25%
The Arc of the United States • 25%
Other • 25%
Music • 25%
Literature • 25%
Film • 25%
Visual Art • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Google • 25%
Microsoft • 25%
Amazon • 25%
Other • 25%
Electronic Arts • 25%
Ubisoft • 25%
Sony Interactive Entertainment • 25%
Other • 25%
Yes • 50%
No • 50%
BAE Systems • 33%
Leonardo • 33%
JAIEC • 33%
Joint leadership • 1%
Other • 25%
Genetic Disorders • 25%
Neuroscience • 25%
Cancer Research • 25%